STOCK TITAN

MIRA Pharmaceuticals reports MIRA-55 receptor findings

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

MIRA Pharmaceuticals, Inc. (MIRA) reported new pharmacological findings for MIRA-55, its investigational oral candidate for inflammatory pain. The company said expanded receptor screening showed more than 500-fold separation from measured mu, delta and kappa opioid receptor interactions, and no substantial COX-1 or COX-2 inhibition at tested concentrations. It reported approximately 680-fold separation from mu opioid receptors and 540-fold from kappa opioid receptors.

Previously reported animal studies found greater pain relief than injected morphine in an acute inflammatory pain model and sustained relief comparable to celecoxib in a separate chronic model, under the conditions tested. MIRA-55 remains in preclinical and IND-enabling activities, with an IND submission targeted for the first half of 2027.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Separation from mu opioid receptors Approximately 680-fold MIRA-55 receptor screening findings
Separation from kappa opioid receptors 540-fold MIRA-55 receptor screening findings
Targeted IND submission First half of 2027 MIRA-55 development outlook
CB2 receptor activation medical
"MIRA-55’s potent CB2 receptor activation"
COX-1 or COX-2 medical
"no substantial inhibition of COX-1 or COX-2"
β-arrestin recruitment technical
"inhibition of agonist-induced β-arrestin recruitment"
Gi/cAMP signaling technical
"limited antagonism of Gi/cAMP signaling"
Gi/cAMP signaling is a cellular communication pathway where G proteins of the Gi family inhibit the enzyme adenylyl cyclase, lowering levels of the messenger molecule cyclic adenosine monophosphate (cAMP) inside the cell. Lower cAMP changes activity of downstream effectors such as protein kinase A and ion channels, altering processes like neurotransmitter release, heart rate, or hormone responses depending on the cell type; the pathway’s effect depends on which receptor activates Gi and which downstream targets are present in that cell.
Investigational New Drug (IND) regulatory
"targeting an Investigational New Drug (IND) submission"
An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.
anxiolytic-like signal medical
"animal studies demonstrated an anxiolytic-like signal"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What receptor selectivity results did MIRA report for MIRA-55?

MIRA reported more than 500-fold separation from measured mu, delta and kappa opioid receptor interactions. It also reported approximately 680-fold separation from mu opioid receptors and 540-fold from kappa opioid receptors, with no substantial COX-1 or COX-2 inhibition at the tested concentrations.

How did MIRA-55 perform in preclinical pain models?

In an acute inflammatory pain model, oral MIRA-55 showed greater pain relief than injected morphine; in a separate chronic inflammatory pain study, it showed sustained pain relief comparable to celecoxib. The comparisons were reported under the conditions tested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001904286 0001904286 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

MIRA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Florida   001-41765   85-3354547
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

1200 Brickell Avenue, Suite 1950 #1183

Miami, Florida 33131

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (786) 432-9792

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   MIRA   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

MIRA-55: New Receptor Selectivity Findings Support a Potentially Differentiated Non-Opioid Approach to Pain

 

On November 16, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) is furnishing information regarding new pharmacological findings for MIRA-55, its investigational oral drug candidate for inflammatory pain. Expanded receptor screening demonstrated substantial separation between MIRA-55’s potent CB2 receptor activation and measured interactions with other biological targets, including more than 500-fold separation from mu, delta, and kappa opioid receptor interactions, respectively. MIRA-55 also showed no substantial inhibition of COX-1 or COX-2 at the tested concentrations. These findings support a potentially differentiated, non-opioid approach to treating inflammatory pain through biological pathways distinct from those targeted by conventional opioid and COX-inhibiting medications.

 

The new findings build on previously reported studies demonstrating potent CB2 activation, measurable CB1 activity, brain penetration following oral administration in animals, and distinct effects on β-arrestin and Gi/cAMP signaling. CB2 helps regulate pain, inflammation, and the body’s response to tissue injury, while CB1 influences how pain signals are transmitted and processed by the nervous system. MIRA-55’s brain penetration may provide an opportunity to influence central pain-processing pathways in addition to peripheral inflammation. Its pathway-dependent pharmacology, characterized by inhibition of agonist-induced β-arrestin recruitment with limited antagonism of Gi/cAMP signaling, may also provide a potential basis for a differentiated CNS behavioral profile.

 

Supporting this pharmacological profile, previously reported animal studies demonstrated encouraging analgesic and anti-inflammatory effects, including greater pain relief than injected morphine in an acute inflammatory pain model and sustained pain relief comparable to celecoxib in a separate chronic inflammatory pain study, under the conditions tested. Additional behavioral studies demonstrated an anxiolytic-like signal and encouraging exploratory behaviors, alongside the absence of significant THC-like motor impairment. Together, these findings support continued development of MIRA-55 as a potentially differentiated treatment for inflammatory pain. The Company is advancing MIRA-55 through preclinical and IND-enabling activities, targeting an Investigational New Drug (IND) submission in the first half of 2027.

 

The Company intends to distribute a press release regarding these findings on November 17, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Cautionary Note Regarding Forward-Looking Statements

 

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.

 

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

 

Forward-looking statements contained in this report speak only as of the date of this report, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

 

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at www.mirapharmaceuticals.com. Forward-looking statements should be considered in light of these risks and uncertainties.

 

Item 9.01 Financial Statements and Other Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release of MIRA Pharmaceuticals, Inc., dated November 17, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MIRA PHARMACEUTICALS, INC.
   
Dated: November 16, 2026 By: /s/ Erez Aminov                 
  Name: Erez Aminov
  Title: Chief Executive Officer

 

 

 

Exhibit 99.1

 

MIRA Pharmaceuticals Reports New MIRA-55 Selectivity Findings Supporting a Differentiated Non-Opioid Approach to Pain

 

New Findings Highlight MIRA-55’s Potent CB2 Activation With More Than 500-Fold Separation From Measured Mu, Delta, and Kappa Opioid Receptor Interactions

 

MIRA-55’s Differentiated Profile Combines CB2/CB1 Activity, Brain Penetration, and Distinct Signaling With Encouraging Preclinical Pain Relief, Reduced Inflammation, and Anxiolytic-Like Effects Without Significant THC-Like Motor Impairment

 

MIAMI, Nov. 17, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company developing novel oral therapies for neurologic, inflammatory and metabolic disorders, today announced new pharmacological findings for MIRA-55, its investigational oral drug candidate for inflammatory pain.

 

Expanded receptor screening demonstrated substantial separation between MIRA-55’s potent CB2 receptor activation and measured interactions with other biological targets, including approximately 680-fold separation from mu opioid receptors and 540-fold separation from kappa opioid receptors. The compound also showed no substantial inhibition of COX-1 or COX-2 at the tested concentrations, suggesting a selective pharmacological approach distinct from conventional opioid and COX-inhibiting pain or anti-inflammatory medications.

 

These findings build on MIRA-55’s previously reported pharmacological and preclinical results, providing additional support for its development as a potentially differentiated non-opioid treatment for inflammatory pain.

 

A Potentially Differentiated Mechanism for Inflammatory Pain

 

MIRA-55’s potential differentiation extends beyond activation of a single receptor. Previously reported studies demonstrated potent CB2 activation alongside measurable CB1 activity, two receptors involved in complementary biological pathways associated with pain and inflammation.

 

CB2 helps regulate inflammation, pain sensitivity, and the body’s response to tissue injury, while CB1 plays an important role in how pain signals are transmitted and processed by the nervous system. Together, these activities raise the possibility that MIRA-55 could address both the underlying inflammatory processes contributing to pain and the neurological pathways involved in pain perception.

 

Previously reported studies also demonstrated that orally administered MIRA-55 reaches brain tissue in animals. This is particularly relevant because pain is not only generated at the site of inflammation but is also processed and regulated by the brain. Brain penetration may therefore provide MIRA-55 with the opportunity to influence central pain-processing pathways in addition to peripheral inflammation.

 

MIRA-55 has also demonstrated distinct effects on β-arrestin and Gi/cAMP signaling, two pathways through which cannabinoid receptors regulate cellular activity. Functional studies showed inhibition of agonist-induced β-arrestin recruitment with limited antagonism of Gi/cAMP signaling. This distinction may be particularly important because broad disruption of CB1 signaling has been associated with psychiatric adverse effects in previously developed cannabinoid-targeting drugs. MIRA-55’s pathway-dependent pharmacology may provide a potential basis for a differentiated CNS behavioral profile. Supporting this possibility, previously reported animal studies demonstrated an anxiolytic-like signal and encouraging exploratory behaviors, alongside the absence of significant THC-like motor impairment.

 

Previously reported animal studies also demonstrated encouraging analgesic and anti-inflammatory effects. In an acute inflammatory pain model, oral MIRA-55 demonstrated greater pain relief than injected morphine, while a separate chronic inflammatory pain study showed sustained pain relief comparable to celecoxib, alongside reductions in inflammation-associated swelling.

 

Scientific Perspective

 

“What makes MIRA-55 particularly compelling is the possibility of addressing pain through complementary biological pathways,” said Dr. Itzchak Angel, CSA of MIRA. “Our findings suggest a pharmacological profile that may influence both the inflammatory processes that contribute to pain and how pain signals are processed in the nervous system. The combination of brain penetration, distinct receptor signaling, a broad receptor selectivity profile, and encouraging preclinical efficacy without significant THC-like motor impairment gives us a strong scientific rationale for believing MIRA-55 could represent a differentiated approach to pain treatment.”

 

 
 

 

Management Commentary

 

“We’re building a differentiated pain franchise focused on significant unmet medical needs,” said Erez Aminov, CEO of MIRA. “MIRA-55 is designed to address inflammatory pain, while Ketamir-2 targets neuropathic pain and is advancing toward Phase 2 proof of concept in chemotherapy-induced peripheral neuropathy. Our strategy is to translate encouraging science into clinical evidence that can support meaningful treatment options for patients and create long-term value through future strategic partnerships.”

 

Development Outlook

 

MIRA continues advancing MIRA-55 through preclinical and IND-enabling activities, targeting an Investigational New Drug (IND) submission in the first half of 2027.

 

Additional preclinical evaluations are ongoing, including measurements of inflammatory cytokines to further characterize MIRA-55’s effects on inflammatory signaling.

 

About MIRA Pharmaceuticals, Inc.

 

MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company developing novel oral therapies designed to address significant unmet medical needs in pain and metabolic disorders. The Company is building a differentiated pain therapeutics franchise alongside an oral obesity program. Its lead candidate, Ketamir-2, is being developed for neuropathic pain, initially targeting chemotherapy-induced peripheral neuropathy (CIPN). Ketamir-2 has successfully completed Phase 1 clinical testing and is advancing toward Phase 2a under an active IND. MIRA’s pipeline also includes MIRA-55, an investigational oral therapy for inflammatory pain, and SKNY-1, an investigational oral therapy for obesity. Following scientific review, the U.S. Drug Enforcement Administration has determined that all three candidates are not classified as controlled substances.

 

About MIRA-55

 

MIRA-55 is an investigational novel oral synthetic cannabinoid analog being developed for inflammatory pain. The compound has demonstrated potent CB2 activation, measurable CB1 activity, brain penetration, and distinct receptor signaling across β-arrestin and Gi/cAMP pathways. Preclinical studies have also shown encouraging analgesic and anti-inflammatory activity, anxiolytic-like effects, and exploratory behavioral findings without significant THC-like motor impairment.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target,” and other words of similar meaning, although not all forward-looking statements include these words. Forward-looking statements may include, but are not limited to, statements regarding the therapeutic potential, mechanism of action, development plans, regulatory pathway, safety profile, efficacy, anticipated clinical development, commercialization prospects, market opportunity, and future development of MIRA-55, SKNY-1, Ketamir-2, and the Company’s other product candidates.

 

These forward-looking statements are based on current expectations, estimates, forecasts, and projections, as well as management’s current beliefs and assumptions, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions, and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K and the Company’s subsequent filings with the U.S. Securities and Exchange Commission (“SEC”).

 

Forward-looking statements contained in this press release speak only as of the date of this press release, and the Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

 

Investors are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding these and other risks and uncertainties is contained in the Company’s filings with the SEC, including its Annual Report on Form 10-K and subsequent filings, available at www.sec.gov and in the Investors section of the Company’s website at www.mirapharmaceuticals.com. Forward-looking statements should be considered in light of these risks and uncertainties.

 

Investor and Media Contact

 

Krystina Quintana

MIRA Pharmaceuticals

info@mirapharma.com

(786) 432-9792

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading